2515 MCKINNEY AVE #1000, DALLAS, TX
Predictive Wound Healing AI + Multispectral Imaging = Faster, More Accurate Treatment Decisions
Announces 2026 Second Quarter Financial Results
Names Darcy Bajko Chief Commercial Officer to Lead Global Sales Launch of FDA-Cleared DeepView® System for Burn Indication
Announces Voting Results of Annual Meeting of Stockholders
Receives FDA De Novo Clearance for DeepView® System for Burn Indication
Offers Employment to Mr. Vincent S. Capone as Chief Executive Officer
Names David McGuire, CPA, as Chief Financial Officer
Earnings Release
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload